Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleOncology Briefs

Endocrine therapies for breast and prostate cancers

Essentials for primary care

Genevieve Chaput and Nureen Sumar
Canadian Family Physician April 2022, 68 (4) 271-276; DOI: https://doi.org/10.46747/cfp.6804271
Genevieve Chaput
Assistant Professor at McGill University in Montreal, Que, an attending physician in the departments of family medicine and secondary care and oncology at the McGill University Health Centre, and Medical Director of the Vaudreuil-Soulanges Palliative Care Residence in Hudson, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nureen Sumar
Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary in Alberta, a faculty member in the Department of Haematology-Oncology at Aga Khan University in Nairobi, Kenya, and Clinical Associate at the Tom Baker Cancer Centre in Calgary.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Breast and prostate cancers are the most common cancers in Canada, occurring in approximately 1 in 8 women and 1 in 8 men, respectively.1 The predicted 5-year survival rate for patients with either cancer is approximately 90%.1 Endocrine therapy is a mainstay treatment for the management of these hormone-sensitive cancers. Although endocrine therapies are associated with improved survival and prolonged time to disease progression, treatment-related side effects can be burdensome, leading to suboptimal adherence.2,3 Primary care providers play an invaluable role in the care of cancer patients and survivors. This article provides an overview of endocrine therapy, with a focus on breast and prostate cancer agents, including indications, clinical pearls, and common side effects and their management.

What is endocrine therapy?

Endocrine therapy is used to treat cancers that use hormones or hormone signaling pathways for growth or survival. At the cellular level, endocrine signaling in cancer cells leads to increased cell proliferation, decreased time available for DNA repair, and increased risk of mutation.4 Endocrine therapy primarily works by interfering with endocrine signaling, blocking hormone synthesis, or targeting hormone receptors.5,6 In the adjuvant setting, these therapies can improve overall survival and decrease risk of cancer recurrence, whereas in the metastatic setting, they might reduce symptom burden.7,8 The type and duration of endocrine therapy is determined by cancer stage at diagnosis, molecular characteristics, prognostic indicators, cancer genomics, endocrine resistance, and tolerance of adverse toxic effects.

Endocrine therapies include corticosteroids, thyroid hormones, somatostatin analogues, and reproductive hormones. Corticosteroids, frequently combined with chemotherapy to increase their effectiveness, are used in the treatment of hematologic cancers (ie, leukemias, lymphomas, and multiple myelomas).5 Thyroid hormones (levothyroxine) are used to inhibit thyroid growth following surgery or radiotherapy for thyroid cancers, or as hormonal replacement therapy after thyroid gland resection.9 Somatostatin analogues (octreotide) are a cornerstone treatment for neuroendocrine tumours and, in particular, reduce symptom burden associated with carcinoid syndrome.8 Finally, and our focus here, reproductive hormones are frequently used to treat cancers requiring male or female hormones to grow, such as breast and prostate cancers.

Endocrine therapy in breast cancer

More than 75% of breast cancers are driven by either estrogen or progesterone.10 Compared with breast cancers that are not hormone receptor–positive, estrogen receptor–positive or progesterone receptor–positive breast cancers are usually associated with improved survival.11 Endocrine therapy is a cornerstone treatment in both adjuvant and metastatic settings of hormone receptor–positive breast cancers; it is also sometimes used as a neoadjuvant therapy. Choice of endocrine regimen is typically determined by clinical, pathologic, and genetic factors, including menopausal status. The main breast cancer endocrine therapies are selective estrogen receptor modulators (eg, tamoxifen), aromatase inhibitors (eg, letrozole, anastrozole, exemestane), and ovarian suppression (ie, via gonadotropin-releasing hormone agonists or surgery). In the adjuvant setting, the choice of endocrine therapy is further determined by low-risk versus high-risk categories, with patients younger than 35 years at diagnosis or needing adjuvant chemotherapy following surgery categorized as high risk (Figure 1).11 Other newer therapies, most used in the metastatic setting, include cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitors (eg, ribociclib, palbociclib), selective estrogen receptor degraders (eg, fulvestrant), and mTOR (mammalian target of rapamycin) inhibitors (eg, everolimus).

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Algorithm for choice of endocrine therapy for breast cancer in the adjuvant setting

Premenopausal patients. In the adjuvant setting, for premenopausal patients at standard risk, tamoxifen is the first-line recommended agent at an oral dose of 20 mg daily for a minimum of 5 years.11 Adjuvant tamoxifen therapy for 5 to 10 years is associated with a statistically significant absolute breast cancer mortality reduction at 15 years (mean [SD] 9.2% [1%]).12,13 For premenopausal patients at high risk of recurrence, tamoxifen or an aromatase inhibitor is recommended in addition to ovarian suppression based on a discussion of risks and benefits with the patient.11

Clinical pearl: Given the risk of inducing estrogen production due to ovarian stimulation, aromatase inhibitors should not be used as a single agent in premenopausal patients. In high-risk patients, aromatase inhibitors coupled with ovarian suppression might be used. Recurrence of menstrual periods during aromatase inhibitor therapy warrants measurement of serum estradiol levels and urgent referral back to an oncology specialist.

Postmenopausal patients. In the adjuvant setting, aromatase inhibitors are the endocrine therapy of choice in postmenopausal patients, for a minimum duration of 5 years. A daily oral dose of letrozole at 2.5 mg, anastrozole at 1 mg, or exemestane at 25 mg can be used. In comparison with tamoxifen, aromatase inhibitors are associated with a statistically significant absolute risk reduction of recurrence at 10 years (3.6%) and an increase in overall survival (2.1%).14

Clinical pearl: Breast cancer recurrence reduction has been demonstrated in patients who switch from tamoxifen to an aromatase inhibitor within the first couple of years of endocrine therapy (2.0%).14 Therefore, patients who reach menopause after 2 to 3 years of taking tamoxifen should be considered for a substitution in their endocrine regimen to aromatase inhibitors.

Endocrine therapy duration. The duration of adjuvant endocrine therapy is typically 5 years.14 Endocrine therapy extension for up to 10 years with either tamoxifen or an aromatase inhibitor might further reduce the risk of breast cancer recurrence in high-risk patients.14 Potential benefits versus potential adverse effects of extended therapy should be carefully assessed by an oncology specialist.11

Side effects and management. An overwhelming majority of patients experience burdensome side effects, causing suboptimal adherence or therapy discontinuation in approximately 30% of patients.3 Primary care providers’ role in active screening and management of these side effects is imperative to alleviate symptom burden, optimize adherence, and prevent rare but potentially serious complications.11 Hot flashes are one of the most frequently reported side effects of tamoxifen, occurring in nearly 80% of patients.15 The mainstay of management includes promotion of lifestyle changes (diet, dressing, bedding) and use of a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.11 Half of patients experience bothersome arthralgias caused by aromatase inhibitors.11 Regular physical exercise, massage therapy, and acupuncture can help alleviate these side effects; the substitution of another aromatase inhibitor might also be helpful.11 Osteoporosis can also result from aromatase inhibitor therapy; supplemental calcium and vitamin D, as well as routine bone mineral density tests, are the mainstay of management.11 Table 1 provides a summary of common side effects of breast cancer endocrine therapies and their respective management.11

View this table:
  • View inline
  • View popup
Table 1.

Breast endocrine therapy: adverse effects and their management

Endocrine therapy in prostate cancer

Approximately 75% of prostate cancer cases are diagnosed at an early stage; the remainder present either with regional nodal disease or as metastatic upon diagnosis.1 Androgen deprivation therapy is a mainstay treatment of prostate cancer and has resulted in a considerable decline in associated mortality rates since 1994.1 More specifically, androgen deprivation therapy is used as the primary systemic therapy for regional or advanced disease and is combined with radiotherapy as neoadjuvant, concurrent, or adjuvant therapy in localized or locally advanced prostate cancers.16 Treatment agents can block the action or the production of androgen throughout the body, or reduce its production from the testicles, thereby reducing cancer cell growth.17 Androgen deprivation can be achieved either surgically (orchiectomy) or medically. Medical therapies include gonadal androgen ablation through luteinizing hormone–releasing hormone agonists (eg, leuprolide, triptorelin, goserelin) or luteinizing hormone– releasing hormone antagonists (eg, degarelix, relugolix); androgen receptor antagonists (eg, bicalutamide, enzalutamide, apalutamide, darolutamide); and adrenal androgen synthesis inhibitors (abiraterone acetate, ketoconazole).18 Medical castration is monitored by assessing circulating testosterone levels. Choice of prostate cancer treatments is determined by a multitude of factors, including stage and grade of cancer at diagnosis, risk of disease progression, expected survival, comorbidities, and family history, as well as patient preference and the side effect profiles of proposed treatments.16,17 Moreover, as initiation of luteinizing hormone–releasing hormone agonists is associated with a testosterone flare, the use of an androgen receptor antagonist is recommended in the first 2 to 4 weeks of therapy.16,18

In patients with intermediate- to high-risk disease, androgen deprivation therapy combined with radiotherapy has been shown to improve survival. Duration of therapy is typically 4 to 6 months for those with intermediate risk, whereas those at higher risk receive continuous androgen deprivation therapy to treat occult systemic disease and reduce the risk of recurrence.16,19 However, androgen deprivation therapy is most often used in the metastatic prostate cancer setting in an intermittent or continuous fashion.19 Worthy of mention, abiraterone has been shown to increase the level of adrenocorticotropic hormone owing to decreased production of cortisol, leading to substantial adverse effects from mineralocorticoid excess (eg, hypertension, fluid retention, hypokalemia).20 To mitigate these adverse effects, glucocorticoids are administered in combination with abiraterone: 5 mg of oral prednisone twice daily is the standard formulation.16,20 Table 2 provides a summary of prostate cancer agents, including their mechanism of action and indications.20

View this table:
  • View inline
  • View popup
Table 2.

Prostate cancer treatments, mechanism of action, and indications

Clinical pearl: Androgen deprivation therapy is not recommended as monotherapy in localized prostate cancer, except in the presence of a contraindication to curative local therapy, such as comorbidities or a prognosis of less than 5 years.16

Side effects and management. Although androgen deprivation therapies have improved oncological outcomes, they are nonetheless associated with several frequently debilitating side effects that adversely affect quality of life.17–19 In turn, care of patients on androgen deprivation therapy is best provided by a multidisciplinary approach that includes active collaboration between the treating specialists and primary care providers.18,19 Androgen deprivation therapy can adversely impact various organ systems and affect bone health, sexual function, and mental health, and lead to cardiovascular disease and metabolic consequences.18,19 Routine screening and prompt management of these potential side effects are of primary importance.18 Table 3 outlines common adverse effects of prostate cancer endocrine therapies and the management of each.18

View this table:
  • View inline
  • View popup
Table 3.

Summary of adverse effects of prostate cancer endocrine therapy and their management

Conclusion

Endocrine therapy is a cornerstone treatment for breast and prostate cancers. While associated with improved survival and reduced risk of cancer recurrence, endocrine therapy treatments are also associated with taxing psychosocial and physical side effects.1,3,12–15,17,18 Family physicians are integral providers of care to cancer patients and survivors: their contributions to the identification and management of endocrine-related side effects are of utmost importance to supporting and optimizing these patients’ overall health and quality of life. Box 1 provides additional useful resources to help guide primary care providers in this important work.18,21–25

Box 1.

Useful resources for primary care providers

Breast cancer

  • Evidence-based approaches for the management of side effects of adjuvant endocrine therapy in patients with breast cancer21: https://www.sciencedirect.com/science/article/abs/pii/S1470204520306665

  • American Society of Clinical Oncology guideline. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer22: https://pubmed.ncbi.nlm.nih.gov/33507815/

Prostate cancer

  • BCGuidelines.ca. Medications for the management of prostate cancer side effects in primary care23: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/prostatecancer-part2_appendixc.pdf

  • Canadian Urological Association guideline on androgen deprivation therapy. Adverse events and management strategies18: https://www.cua.org/system/files/Guideline-Files/7355_v8.pdf

  • Cancer Care Ontario. Managing symptoms, side effects, and well-being24: https://www.cancercareontario.ca/en/symptom-management

Cardiovascular effects of breast and prostate cancer endocrine therapies

  • American Heart Association. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system25: https://www.ahajournals.org/doi/epub/10.1161/HCG.0000000000000082

Footnotes

  • Competing interests

    None declared

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à https://www.cfp.ca dans la table des matières du numéro d’avril 2022 à la page e120.

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Canadian Cancer Statistics Advisory Committee, Canadian Cancer Society, Statistics Canada, Public Health Agency of Canada
    . Canadian cancer statistics 2021. Toronto, ON: Canadian Cancer Society; 2021. Available from: https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2021-statistics/2021-pdf-en-final.pdf. Accessed 2022 Jan 29.
  2. 2.↵
    1. Pilon D,
    2. LaMori J,
    3. Rossi C,
    4. Durkin M,
    5. Ghelerter I,
    6. Ke X, et al.
    Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncol 2022;18(2):231-43. Epub 2021 Nov 3.
    OpenUrl
  3. 3.↵
    1. Berkowitz MJ,
    2. Thompson CK,
    3. Zibecchi LT,
    4. Lee MK,
    5. Streja E,
    6. Berkowitz JS, et al.
    How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv 2021;15(1):29-39. Epub 2020 Aug 17.
    OpenUrl
  4. 4.↵
    1. Cleator SJ,
    2. Ahamed E,
    3. Coombes RC,
    4. Palmieri C
    . A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 2009;9(Suppl 1):S6-17.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Hormone therapy to treat cancer. Bethesda, MD: National Cancer Institute. Available from: https://www.cancer.gov/about-cancer/treatment/types/hormone-therapy. Accessed 2022 Jan 8.
  6. 6.↵
    1. Sleightholm R,
    2. Neilsen BK,
    3. Elkhatib S,
    4. Flores L,
    5. Dukkipati S,
    6. Zhao R, et al.
    Percentage of hormone receptor positivity in breast cancer provides prognostic value: a single-institute study. J Clin Med Res 2021;13(1):9-19. Epub 2021 Jan 12.
    OpenUrl
  7. 7.↵
    1. Cao L,
    2. Sugumar K,
    3. Keller E,
    4. Li P,
    5. Rock L,
    6. Simpson A, et al.
    Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes. Ann Surg Oncol 2021;28(10):5730-41. Epub 2021 Aug 3.
    OpenUrl
  8. 8.↵
    1. Hofland J,
    2. Herrera-Martínez AD,
    3. Zandee WT,
    4. de Herder WW
    . Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019;26(3):R145-56.
    OpenUrlPubMed
  9. 9.↵
    1. Schlumberger M,
    2. Leboulleux S
    . Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 2021;17(3):176-88. Epub 2020 Dec 18.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Howlader N,
    2. Altekruse SF,
    3. Li CI,
    4. Chen VW,
    5. Clarke CA,
    6. Ries LA, et al.
    US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106(5):dju055.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Awan A,
    2. Esfahani K
    . Endocrine therapy for breast cancer in the primary care setting. Curr Oncol 2018;25(4):285-91. Epub 2018 Aug 14.
    OpenUrl
  12. 12.↵
    1. Early Breast Cancer Trialists’ Collaborative Group
    . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Early Breast Cancer Trialists’ Collaborative Group
    . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386(10001):1341-52. Epub 2015 Jul 23.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Loibl S,
    2. Poortmans P,
    3. Morrow M,
    4. Denkert C,
    5. Curigliano G
    . Breast cancer. Lancet 2021;397(10286):1750-69. Epub 2021 Apr 1. Erratum in: Lancet 2021;397(10286):1710.
    OpenUrlPubMed
  15. 15.↵
    1. Day R
    . Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 2001;949:143-50.
    OpenUrlPubMed
  16. 16.↵
    NCCN clinical practice guidelines in oncology: prostate cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2022.
  17. 17.↵
    1. Edmunds K,
    2. Tuffaha H,
    3. Galvão DA,
    4. Scuffham P,
    5. Newton RU
    . Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer 2020;28(5):2079-93. Epub 2020 Jan 7.
    OpenUrlPubMed
  18. 18.↵
    1. Kokorovic A,
    2. So AI,
    3. Serag H,
    4. French C,
    5. Hamilton RJ,
    6. Izard JP, et al.
    Canadian Urological Association guideline on androgen deprivation therapy: adverse events and management strategies. Can Urol Assoc J 2021;15(6):E307-22. Erratum in: Can Urol Assoc J 2021;15(7):E383.
    OpenUrl
  19. 19.↵
    1. Magee DE,
    2. Singal RK
    . Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol 2020;27(Suppl 1):11-6.
    OpenUrl
  20. 20.↵
    1. Desai K,
    2. McManus JM,
    3. Sharifi N
    . Hormonal therapy for prostate cancer. Endocr Rev 2021;42(3):354-73.
    OpenUrl
  21. 21.↵
    1. Franzoi MA,
    2. Agostinetto E,
    3. Perachino M,
    4. Del Mastro L,
    5. de Azambuja E,
    6. Vaz-Luis I, et al.
    Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol 2021;22(7):e303-13. Epub 2021 Apr 20.
    OpenUrl
  22. 22.↵
    1. Korde LA,
    2. Somerfield MR,
    3. Carey LA,
    4. Crews JR,
    5. Denduluri N,
    6. Hwang ES, et al.
    Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 2021;39(13):1485-505. Epub 2021 Jan 28.
    OpenUrl
  23. 23.↵
    1. BCGuidelines.ca
    . Appendix C: medications for the management of prostate cancer side effects in primary care. Vancouver, BC: Guidelines and Protocols and Advisory Committee, Government of British Columbia; 2020. Available from: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/prostatecancer-part2_appendixc.pdf. Accessed 2022 Jan 15.
  24. 24.↵
    Managing symptoms, side effects & well-being. Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/en/symptom-management. Accessed 2022 Jan 6.
  25. 25.↵
    1. Okwuosa TM,
    2. Morgans A,
    3. Rhee JW,
    4. Reding KW,
    5. Maliski S,
    6. Plana JC, et al.
    Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021;14(3):e000082. Epub 2021 Apr 26.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (4)
Canadian Family Physician
Vol. 68, Issue 4
1 Apr 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Endocrine therapies for breast and prostate cancers
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Endocrine therapies for breast and prostate cancers
Genevieve Chaput, Nureen Sumar
Canadian Family Physician Apr 2022, 68 (4) 271-276; DOI: 10.46747/cfp.6804271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Endocrine therapies for breast and prostate cancers
Genevieve Chaput, Nureen Sumar
Canadian Family Physician Apr 2022, 68 (4) 271-276; DOI: 10.46747/cfp.6804271
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • What is endocrine therapy?
    • Endocrine therapy in breast cancer
    • Endocrine therapy in prostate cancer
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Thérapies endocriniennes contre les cancers du sein et de la prostate
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Common oncologic emergencies
  • Vaccination considerations for patients receiving cancer therapy
  • Targeted cancer therapies
Show more Oncology Briefs

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire